Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Werewolf Therapeutics (HOWL) Capital Expenditures (2021 - 2024)

Werewolf Therapeutics (HOWL) has disclosed Capital Expenditures for 4 consecutive years, with -$124000.0 as the latest value for Q4 2024.

  • On a quarterly basis, Capital Expenditures fell 121.72% to -$124000.0 in Q4 2024 year-over-year; TTM through Sep 2025 was -$124000.0, a 117.84% decrease, with the full-year FY2023 number at $769000.0, down 78.7% from a year prior.
  • Capital Expenditures was -$124000.0 for Q4 2024 at Werewolf Therapeutics, down from -$4000.0 in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $1.9 million in Q2 2022 to a low of -$124000.0 in Q4 2024.
  • A 4-year average of $304875.0 and a median of $95000.0 in 2023 define the central range for Capital Expenditures.
  • Peak YoY movement for Capital Expenditures: surged 30983.33% in 2022, then plummeted 121.72% in 2024.
  • Werewolf Therapeutics' Capital Expenditures stood at $418000.0 in 2021, then grew by 23.92% to $518000.0 in 2022, then increased by 10.23% to $571000.0 in 2023, then tumbled by 121.72% to -$124000.0 in 2024.
  • Per Business Quant, the three most recent readings for HOWL's Capital Expenditures are -$124000.0 (Q4 2024), -$4000.0 (Q3 2024), and $17000.0 (Q2 2024).